Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

NCT06574503 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

748

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

DRUG: GP681 40mg
DRUG: GP681 Simulant

Sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd.